This 2017 erratum pertains to a correction of the original 2016 publication that investigated the ototoxic potential of artesunate when administered as an add-on therapy in patients with metastatic or locally advanced breast cancer. The original study, a phase I trial, was prospective, open-label, and single-center in design, aiming to
